ASAP1 as a novel dual-level biomarker for tuberculosis: integrated genetic and proteomic evidence for early detection and disease monitoring
摘要
Tuberculosis (TB) remains a major global health challenge, with limitations in current diagnostics prompting interest in host-derived biomarkers. This study evaluated the role of ASAP1, a regulator of actin cytoskeleton remodeling and dendritic cell migration, as a genetic and molecular biomarker for TB. A case–control cohort comprising 164 TB patients and 85 healthy controls was analyzed for two intronic ASAP1 single-nucleotide polymorphisms (SNPs), rs4733781 (A > C) and rs10956514 (G > A), along with peripheral blood mRNA expression and serum protein levels.
Methodology and resultsGenotypic analysis revealed no significant differences in allele frequencies between groups; however, rs4733781 was significantly associated with TB under the dominant genetic model (OR = 1.95, 95% CI = 1.08–3.53, p = 0.04). Haplotype analysis identified a C–G–A–G configuration as more frequent in TB cases (OR = 15.78, p = 0.02). Expression quantitative trait loci (eQTL) data confirmed genotype-dependent variation in ASAP1 transcript levels. In this cohort, qPCR demonstrated markedly elevated ASAP1 mRNA expression in TB patients versus controls (mean 9.39-fold vs 1.26-fold; p < 0.001; AUC = 0.84), with a threshold of 5.134-fold yielding 75.0% sensitivity and 100% specificity. ELISA measurements showed higher serum ASAP1 protein levels in TB patients without rifampicin resistance compared to controls (median 137.61 vs. 65.71 ng/mL; p = 0.002; AUC = 0.64). The “either-positive” combination of mRNA and protein thresholds improved sensitivity to 92.1% while maintaining 85.5% specificity, whereas the “both-positive” rule achieved perfect specificity but lower sensitivity (51.3%).
ConclusionProtein–protein interaction analysis linked ASAP1 to immune regulatory and cytoskeletal proteins, supporting its functional relevance in TB pathogenesis. These findings suggest that ASAP1, at both transcript and protein levels, is a promising candidate for inclusion in biomarker panels, with potential applications in confirmatory diagnosis and high-yield screening strategies. Further validation in larger, diverse, and longitudinal cohorts is warranted.